Vaxiion Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Vaxiion Therapeutics sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Vaxiion Therapeutics: 2 sponsored US clinical trials, 1 recruiting.
Vaxiion Therapeutics sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab, with 1 trials.
Mid-pack sponsor footprint
Vaxiion Therapeutics is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
NCT05901285
A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer
NCT03854721
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
What is open in the Vaxiion Therapeutics pipeline
1 recruiting of 2 indexed (50% open); 1 completed (50%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Vaxiion Therapeutics: open-pipeline peers nationwide
Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Vaxiion Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
- Abcentra · 50% recruiting · 2 trials
Related
What to do with this Vaxiion Therapeutics page
2 registered trials is a research-attention snapshot, not an endorsement of Vaxiion Therapeutics or any single study.
- 1 of Vaxiion Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab is the condition Vaxiion Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Vaxiion Therapeutics pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.